Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.22 apiece, ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $14.00. The company’s shares closed last ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target of $6.00. The company’s shares closed yesterday ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...